Study results from University of Pittsburgh broaden understanding of thyroid cancer
2009 JUL 27 - (NewsRx.com) -- According to a study from the United States, "BRAF gene mutations are identified in about 45% of papillary thyroid carcinomas (PTC) and represent the most common genetic event in this tumor. Here, we report a case of PTC, solid variant, with a complex BRAF mutation that involves one nucleotide substitution, C1796T, and a CTT triplet insertion, 1798_1799insCTT, located on the same allele." "This mutation leads to the replacement of a threonine with an isoleucine, T599I, and replacement of a valine with an alanine and a leucine, V600delinsAL. This mutation was identified both in the preoperative fine needle aspirate sample and in the surgical specimen after total thyroidectomy," wrote S. Chiosea and colleagues, University of Pittsburgh. The researchers concluded: "Other rare BRAF mutations in PTC are reviewed." Chiosea and colleagues published their study in Endocrine Pathology (A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. Endocrine Pathology, 2009;20(2):122-126). For more information, contact S. Chiosea, University of Pittsburgh, Presbyterian Hospital, Dept. of Pathology, Medical Center, PUH A616-2, 200 Lothrop St., Pittsburgh, PA 15213, USA. Publisher contact information for the journal Endocrine Pathology is: Humana Press Inc., 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA. Keywords: United States, Pittsburgh, Endocrine, Oncology, Papillary Thyroid Cancer, Pathology, Thyroid Carcinoma, University of Pittsburgh. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
